ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy

Kantae, Vasudev; Krekels, Elke H. J.; Van Esdonk, Michiel J.; Lindenburg, Peter; Harms, Amy C.; Knibbe, Catherijne A. J.; Van der Graaf, Piet H.; Hankemeier, Thomas*
Metabolomics2017-1DOI: 10.1007/s11306-016-1143-1
64被引2阅读
引用收藏
分享

摘要

Personalized medicine, in modern drug therapy, aims at a tailored drug treatment accounting for inter-individual variations in drug pharmacology to treat individuals effectively and safely. The inter-individual variability in drug response upon drug administration is caused by the interplay between drug pharmacology and the patients' (patho)physiological status. Individual variations in (patho) physiological status may result from genetic polymorphisms, environmental factors (including current/past treatments), demographic characteristics, and disease related factors. Identification and quantification of predictors of inter-individual variability in drug pharmacology is necessary to achieve personalized medicine. Here, we highlight the potential of pharmacometabolomics in prospectively informing on the inter-individual differences in drug pharmacology, including both pharmacokinetic (PK) and pharmacodynamic (PD) processes, and thereby guiding drug selection and drug dosing. This review focusses on the pharmacometabolomics studies that have additional value on top of the conventional covariates in predicting drug PK. Additionally, employing pharmacometabolomics to predict drug PD is highlighted, and we suggest not only considering the endogenous metabolites as static variables but to include also drug dose and temporal changes in drug concentration in these studies. Although there are many endogenous metabolite biomarkers identified to predict PK and more often to predict PD, validation of these biomarkers in terms of specificity, sensitivity, reproducibility and clinical relevance is highly important. Furthermore, the application of these identified biomarkers in routine clinical practice deserves notable attention to truly personalize drug treatment in the near future.

学科与关键词

关键词
Personalized medicinePharmacologyPharmacokineticsPharmacodynamicsPharmacometabolomicsMetabolomicsBiomarker
相关
加载中…
  • Metabolomics: a tool for personalizing medicine?
    Schnackenberg, Laura K.*; Kaput, Jim; Beger, Richard D.Personalized Medicine, 2008, 5(5): 495-504.被引 7
  • Pharmacogenomics: a key component of personalized therapy
    Matthias, Schwab; Elke, SchaeffelerGenome Medicine, 2012, 4(11): 93.被引 16
  • Pharmacogenomics in Personalized Drug Therapy
    Masahiro HiratsukaSEIBUTSU BUTSURI KAGAKU, 2012, 58(1): 1-4.
查看全部 →

发表信息

论文状态
公开发表
期刊
Metabolomics
发表日期
2017-01
卷期
第 13 卷, 第 1 期
页码
9
DOI
10.1007/s11306-016-1143-1
语言
ENGLISH
期刊等级
Q2
成果收录
SCIE
资助标注
Faculty of Science ("Profiling programme: Endocannabinoids"), Leiden University; SysMedPD within the European Union [668738]

作者

  • K

    Kantae, Vasudev (第一作者)

  • K

    Krekels, Elke H. J.

查看全部 8 位作者收起作者
  • V

    Van Esdonk, Michiel J.

  • L

    Lindenburg, Peter

  • H

    Harms, Amy C.

  • K

    Knibbe, Catherijne A. J.

  • V

    Van der Graaf, Piet H.

  • H

    Hankemeier, Thomas (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417